Status:
RECRUITING
Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis
Lead Sponsor:
Khyber Medical University Peshawar
Conditions:
Hemophilia
Chronic Synovitis
Eligibility:
All Genders
Phase:
NA
Brief Summary
Hemophilia is an inherited bleeding disorder characterized by deficiency of clotting factors, leading to increased bleeding tendencies. The most common complications are joint bleeds (hemarthroses), w...
Detailed Description
Hemophilia A is the most prevalent inherited bleeding disorder in Pakistan, accounting for approximately 69% of all hemophilia cases. A major complication is recurrent joint bleeding (hemarthrosis), w...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of Hemophilia A.
- Presence of one or more target joints (knee, elbow, ankle) with chronic synovitis and a history of \>2 hemarthrosis episodes in the past 6 months.
- Target joint World Federation of Hemophilia (WFH) joint score of 2-3.
- Adequate hematological, renal, and liver function (as specified by protocol lab values).
- Ability and willingness to provide informed consent and comply with the study protocol.
Exclusion
- HIV positive diagnosis.
- Severely damaged joints or anatomical limitations preventing safe injection.
- Contraindications to MRI.
- Uncontrolled hypertension.
- Recent major surgery/trauma (\<28 days).
- Serious non-healing wound, active cardiovascular disease, or other significant comorbidities that could increase risk or interfere with the study.
Key Trial Info
Start Date :
September 9 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 15 2026
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT07187661
Start Date
September 9 2025
End Date
April 15 2026
Last Update
September 23 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hayatabad Medical Complex
Peshawar, KPK, Pakistan, 25000
2
Institute of Pathology and Diagnostic Medicine (IPDM)
Peshawar, KPK, Pakistan, 25000